Another beat; we appreciate the new CEO's aggressive intent
28/07/26 -"The Q2 results were ahead of expectations, backed by strong growth across GSK’s key focus areas. The management maintained its full-year guidance. Also, a new cost savings plan was announced to ..."
Pages
68
Language
English
Published on
28/07/26
You may also be interested by these reports :
28/07/26
The Q2 results were ahead of expectations, backed by strong growth across GSK’s key focus areas. The management maintained its full-year guidance. ...
27/07/26
The Q2 26 results were largely in line with the street’s expectations. Strong growth in oncology, respiratory, immunology and rare disease treatments ...
23/07/26
Despite FX headwinds, the Q2 results were ahead of the street’s expectations. The performance was driven by drugs across therapeutic areas, and the ...
22/07/26
Lonza published its 1H results, with a strong operating performance but a mixed revenue outcome. The group grew by +16% (CER) YoY, with strong FX ...